FIG. 5


Spleen
(OT-I – CD3+CD8+)
Lymph Node
(OT-II – CD3+CD4+)
Challenge Control
Tolerance Control
B cell-Endo
B cell-SQZ
1.47%
0.79%
1.54%
0.32%
0.77%
0.13%
0.57%
0.15%
TCRVa2
CD45.2

FIG. 6


IFN-γ Responsive OT-I T Cells in Spleen
79.6%
Challenge Control
67.8%
Tolerance Control
77.6%
B cell-Endo
54.8%
B cell-SQZ
IFN-γ
CD44

FIG. 10


Challenge Control
Naive
SQZ-OVA
Tolerance Control
20.8%
1.49%
1.52%
2.55%
87.1%
1.37%
15.5%
26.0%
OT-I T cells (CD45.2) CD8+ T Cells
IFN-γ
CD44

FIG. 5


Spleen
(OT-I – CD3+CD8+)
Lymph Node
(OT-II – CD3+CD4+)
Challenge Control
Tolerance Control
B cell-Endo
B cell-SQZ
1.47%
0.79%
1.54%
0.32%
0.77%
0.13%
0.57%
0.15%
TCRVa2
CD45.2

FIG. 6


IFN-γ Responsive OT-I T Cells in Spleen
79.6%
Challenge Control
67.8%
Tolerance Control
77.6%
B cell-Endo
54.8%
B cell-SQZ
IFN-γ
CD44

FIG. 10


Challenge Control
Naïve
SQZ-OVA
Tolerance Control
20.8%
1.49%
1.52%
2.55%
87.1%
1.37%
15.5%
26.0%
OT-I T Cells (CD45.2)
CD8+ T Cells
IFN-γ
CD44